Critical care – COVID-19.
Implement new modalities to modify the thromboinflammatory process by further elucidating the underlying mechanisms.
Unveil the details of the crosstalk between the inflammatory response and hemostasis in critically ill patients.
Higher-dose anticoagulation cannot prevent disease progression in COVID-19 patients: a systematic review and meta-analysis.
Effectiveness and safety of fibrinolytic therapy in critically ill COVID-19 patients with ARDS: systematic review and a prospective meta-analysis.
Effectiveness and safety of fibrinolytic therapy in critically ill COVID-19 patients with ARDS: an explorative registry analysis.
Association between immunomodulation with interleukin-6 antagonists and the coagulation system in critically ill COVID-19 patients: a prospective observational study.
Publications
- Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis - IF: 2.900, Quality: Q1, Journal: BMJ Open
- Effectiveness and safety of fibrinolytic therapy in critically ill patients with COVID-19 with ARDS: protocol for a prospective meta-analysis - IF: 2.900, Quality: Q1, Journal: BMJ Open
- Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study - IF: 2.900, Quality: Q1, Journal: BMJ Open